- For the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication
AND
Drug | Dosing Regimen | Dose Limit/ Maximum Dose |
---|---|---|
carbidopa/levodopa extended release (Sinemet CR) | 25 mg/100 mg PO BID; 50 mg/200 mg PO BID | 12 tablets/day |
carbidopa/levodopa immediate release (Sinemet, Parcopa) | 10 mg/100 mg PO TID to QID; 25 mg/100 mg PO TID | carbidopa 200 mg/day |
carbidopa/levodopa/entacapone (Stalevo) | Individualized based on therapeutic response | 6 tablets/day of Stalevo 200; 8 tablets/day of Stalevo 50, 75, 100, 125, 150 |
Drug | Dosing Regimen | Authorization Limit |
---|---|---|
Rytary | Levodopa-naive patients Starting dose 23.75 mg/95 mg PO TID; may increase to 36.25 mg/145 mg PO TID on the fourth day of treatment. Based on clinical response and tolerability, dose may be increase to a maximum of 97.5 mg/390 mg PO TID Converting patients taking carbidopa/levodopa IR products: Refer to dosing table in prescribing information. Dosages of other carbidopa and levodopa products are not interchangeable with Rytary. | Length of Benefit |